Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.71 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | MITF | O75030 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21011278 | 0.86 | SLC29A1 (0.76) | TP53SLC29A1ADORA3SMN1; SMN2HIF1A | |
| SCHEMBL27183207 | 0.86 | SLC29A1 (0.76) | TP53SLC29A1ADORA3SMN1; SMN2HIF1A | |
| SCHEMBL2288114 | 0.86 | SLC29A1 (0.76) | TP53SLC29A1ADORA3SMN1; SMN2HIF1A | |
| SCHEMBL23982135 | 0.86 | SLC29A1 (0.76) | TP53SLC29A1ADORA3SMN1; SMN2HIF1A | |
| SCHEMBL14873532 | 0.86 | SLC29A1 (0.76) | TP53SLC29A1ADORA3SMN1; SMN2HIF1A | |
| SCHEMBL23982158 | 0.86 | SLC29A1 (0.76) | TP53SLC29A1ADORA3SMN1; SMN2HIF1A | |
| SCHEMBL2288108 | 0.86 | SLC29A1 (0.76) | TP53SLC29A1ADORA3SMN1; SMN2HIF1A | |
| SCHEMBL19583057 | 0.85 | SLC29A1 (0.65) | TP53PAX8SLC29A1ADORA3SMN1; SMN2 | |
| SCHEMBL19583149 | 0.84 | SLC29A1 (0.64) | SLC29A1HIF1A | |
| SCHEMBL19583122 | 0.84 | SLC29A1 (0.64) | TP53PAX8SLC29A1ADORA3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229771-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2024-04-03 | — | — | EP | disclosed |
| EP-3229772-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2020-04-29 | — | — | EP | disclosed |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-02-04 | — | — | US | disclosed |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-10-16 | — | — | US | disclosed |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-23 | — | — | US | disclosed |
| US-20170326168-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326168-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | GART, DAO, GLA | TP53 3135/4885PAX8 4070/4885SLC29A1 125/4885 |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | GART, DAO, GLA | TP53 3135/4885PAX8 4070/4885SLC29A1 125/4885 |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNG, FUT6, GART | TP53 2090/4885PAX8 3745/4885SLC29A1 59/4885 |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNG, FUT6, GART | TP53 2090/4885PAX8 3745/4885SLC29A1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.